ModeX Therapeutics Secures $35M BARDA Supplement For COVID Multispecific Antibodies And $16M For Influenza Program; Total BARDA Awards Now At $110M With Potential To Reach $205M If All Options Are Exercised
Portfolio Pulse from Benzinga Newsdesk
ModeX Therapeutics has secured additional funding from BARDA, receiving $35M for COVID multispecific antibodies and $16M for an influenza program. The total BARDA awards for ModeX now stand at $110M, with potential to reach $205M if all options are exercised. This funding supports the development of ModeX's MSTAR technology to address emerging viral threats.
October 07, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ModeX Therapeutics, a subsidiary of OPKO Health (OPK), has received significant BARDA funding for its COVID and influenza programs. This could enhance OPKO's revenue and market position in the biotech sector.
ModeX Therapeutics, part of OPKO Health, received $51M in BARDA funding, with potential for more. This funding supports key programs and could positively impact OPKO's financials and market perception.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80